Text Size:AAA


Sino Biological offers a comprehensive set of tools for protein kinase related research, including recombinant proteins, antibodies, ELISA kits, and cDNA clones.

Product CategoriesProteinsAntibodiesELISA KitscDNA Clones
Number of Products

蛋白激酶 Related Products Index

    蛋白激酶 Related Products by Product Type

    蛋白激酶 By Species

    蛋白激酶 by Signaling Pathways

    蛋白激酶 Background

    Protein kinases modify their target proteins by transferring phosphate groups from ATP to serine, threonine, or tyrosine residues on them (phosphorylation). Phosphorylation usually results in a functional change of the substrate by changing enzyme activity, intracellular location, or association with other proteins. Protein kinases are particularly prominent in signal transduction and are known to regulate the majority of cell processes, such as cell growth, differentiation, metabolism, gene transcription, and so on. Most kinases act on both serine and threonine, others act on tyrosine, and a number act on all three. Serine/threonine protein kinases phosphorylate the OH group of serine or threonine amino acid residues. These protein kinases are usually stimulated by numerous chemical signals, including cAMP/cGMP, Ca2+/calmodulin, diacylglycerol. Tyrosine-specific protein kinases that phosphorylate tyrosine amino acid residues act primarily as growth factor receptors and in downstream signaling from growth factors. Abnormal activity of protein kinases is a frequent cause of disease, particularly cancer. Protein kinases have emerged as one of the most frequently targeted families of proteins in drug discovery. The development of small-molecule inhibitors that have the potency and selectivity necessary to be effective cancer drugs has gained notable successes over the past decades.

    蛋白激酶 References

      1. Hunter T (1991). Protein kinase classification. Meth. Enzymol. 200:3-37.
      2. Higashiyama S, et al. (2008) Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 99(2):214-20.
      3. Zarate CA, et al. (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs. 23(7):569-82.
      4. Feng Y, et al. (2009) p38 Mitogen-activated protein kinase and hematologic malignancies. Arch Pathol Lab Med. 133(11):1850-6.
      5. Krishnamurty R, et al. (2010) Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol. 5(1):121-38.